Stopped: COVID restrictions
The purpose of this study is to assess the duration of time (in weeks) for improvement in objective dry eye markers for people who are placed on lifitegrast 0.5% (Xiidra®), an FDA-approved therapy for dry eyes.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
The change in proportion of subjects demonstrating improved tear film osmolarity
Timeframe: Baseline, Weeks 1, 2, 3 and 4